These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 35426909)

  • 1. Risks to the 340B Drug Pricing Program Related to Manufacturer Restrictions on Drug Availability.
    Knox RP; Kesselheim AS; Sarpatwari A
    JAMA; 2022 May; 327(17):1647-1648. PubMed ID: 35426909
    [No Abstract]   [Full Text] [Related]  

  • 2. Policy Statement on the 340B Drug Pricing Program by the American Society of Clinical Oncology.
    American Society of Clinical Oncology
    J Oncol Pract; 2014 Jul; 10(4):259-63. PubMed ID: 24737877
    [No Abstract]   [Full Text] [Related]  

  • 3. Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door.
    Yang YT; Chen B; Bennett CL
    J Clin Oncol; 2016 Dec; 34(36):4320-4322. PubMed ID: 27998222
    [No Abstract]   [Full Text] [Related]  

  • 4. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    Health Care Law Mon; 2007 Aug; ():3-12. PubMed ID: 17955590
    [No Abstract]   [Full Text] [Related]  

  • 5. Value of the 340B Drug Discount Program.
    Kantarjian H; Chapman R
    JAMA Oncol; 2015 Nov; 1(8):1029-30. PubMed ID: 26313652
    [No Abstract]   [Full Text] [Related]  

  • 6. The 340B Drug Pricing Program: an opportunity for savings, if covered entities such as disproportionate share hospitals and federally qualified health centers know how to interpret the regulations.
    Werling K; Abraham S; Strelec J
    J Health Care Finance; 2007; 34(2):57-70. PubMed ID: 18972994
    [No Abstract]   [Full Text] [Related]  

  • 7. 340B Drug Pricing Program Ceiling Price and Manufacturer Civil Monetary Penalties Regulation. Final rule; further delay of effective date.
    Health Resources and Services Administration, HHS
    Fed Regist; 2017 May; 82(96):22893-5. PubMed ID: 28574239
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Notice regarding Section 602 of the Veterans Health Care Act of 1992; new drug pricing--PHS. Final notice.
    Fed Regist; 1995 Oct; 60(190):51488-9. PubMed ID: 10151188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eliminating innovation: how price controls limit access.
    Ingram J
    J Leg Med; 2011 Jan; 32(1):115-28. PubMed ID: 21391059
    [No Abstract]   [Full Text] [Related]  

  • 10. Medicaid payment for generic drugs: achieving savings and access.
    Peters CP
    Issue Brief George Wash Univ Natl Health Policy Forum; 2010 Sep; (839):1-16. PubMed ID: 20928958
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Notice regarding HRSA grant requirement--participation in the 340B drug pricing program--HRSA. Notice.
    Fed Regist; 1998 Oct; 63(204):56656-8. PubMed ID: 10187117
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fair global drug pricing.
    Campbell JD; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2018 Dec; 18(6):581-583. PubMed ID: 30215535
    [No Abstract]   [Full Text] [Related]  

  • 13. These doctor's mission: keeping drug costs down.
    Guglielmo WJ
    Med Econ; 2001 Apr; 78(8):108-10, 113-6. PubMed ID: 11386066
    [No Abstract]   [Full Text] [Related]  

  • 14. Trying to get control of drug costs, Florida earns kudos--and a lawsuit.
    Carlson B
    Manag Care; 2001 Oct; 10(10):17, 21. PubMed ID: 11764743
    [No Abstract]   [Full Text] [Related]  

  • 15. Prescription drug prices in the US.
    Med Lett Drugs Ther; 2017 May; 59(1521):81-83. PubMed ID: 28520697
    [No Abstract]   [Full Text] [Related]  

  • 16. Providers offer prescription for Medicaid drug-pricing law.
    Chaconas J
    Trustee; 1991 Dec; 44(12):12, 19. PubMed ID: 10115321
    [No Abstract]   [Full Text] [Related]  

  • 17. 340B Drug Pricing Program Reform.
    Fong WH
    JAMA Oncol; 2016 Mar; 2(3):403. PubMed ID: 26967190
    [No Abstract]   [Full Text] [Related]  

  • 18. What's at stake in effort to diminish 340B program.
    Henkel B
    Mod Healthc; 2014 Sep; 44(39):34. PubMed ID: 25509599
    [No Abstract]   [Full Text] [Related]  

  • 19. Estimates of the Number of Brand-name Drugs Affected by the Medicaid Rebate Cap in 2017.
    Dickson S
    JAMA Intern Med; 2019 Mar; 179(3):437-439. PubMed ID: 30667469
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 340B Drug Pricing Program Reform-Reply.
    Kantarjian H; Chapman R
    JAMA Oncol; 2016 Mar; 2(3):403-4. PubMed ID: 26967191
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.